Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy.

Vasc Health Risk Manag · 2008 · PMC2464765 · PMID 18629370

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Atrial tachyarrhythmias also showed a trend toward reduction, while hospital admission for myocardial infarction showed a trend toward reduction in CHARM Added and CHARM Preserved. ‘Other’ cardiovascular admissions were fewer in the candesartan group in CHARM Alternative and CHARM-Added, and just nominally greater in the candesartan group in CHARM-Preserved.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.